Advancement in fish and genomic instabilityCymoGen Dx, LLC is dedicated to providing Next-Gen FISH™ research products for clinical, research and biopharmaceutical customers. Our management and scientific teams are among a small number of world leaders in the application and commercialization of fluorescence-based DNA probe detection technology. Since its inception in the early 1990's FISH has become a uniformed and routine laboratory platform for molecular pathology and cytogenetics. It has become the gold standard for identifying genomic variations related to loss, gain and rearrangements/translocations. Over the past five years a new era of identifying and stratifying genomic instability (aberrations) in tumors has lead to ground breaking results in understanding cancer and associated complexities. CymoGen Dx now brings Next-Gen FISH Probes™ that take advantage of the latest advances in science and work with all existing imaging systems and filter sets. Our novel Selected Sequence Design™ (SSD™) probes with no added Cott 1 or blocking agents and our proprietary labeling system results in probes that are smaller and brighter with significantly higher signal to noise ratio. Easier to use and with true technical support, these probes are so consistent in quality that they come with a full replacement guarantee. With unique patent pending platform technology, CymoGen Dx has also overcome the complexities and difficulties associated with formalin fixed paraffin embedded (FFPE) specimens and their analysis. This breakthrough technology will provide unprecedented accuracy and ease of use in this rapidly expanding area of FISH. The CymoGen Dx mission is to discover, develop, manufacture and market genomic reagents of the highest quality, sensitivity and efficacy for global human genomic research and disease profiling. We are dedicated to providing cost-effective products combined with superior customer and technical support. Our Next-Gen FISH™ reagents are designed for identifying genomic aberrations in cancer cells found in FFPE tissues, bone marrow, aspirates and blood specimens. We produce Next-Gen genomic-based reagents and fluorescent In-Situ hybridization ("FISH") probes for numerous cancers both hematologic and solid tumors. The combination of our novel FISH Probe technology with cell isolation techniques as well as proprietary patent pending platform technology that provides unprecedented analytical accuracy for Formalin Fixed, Paraffin Embedded specimens has raised the bar on performing more precise analysis for the chromosomal chaos evident in specific cancers. Novel Innovations in FISH Technology
|
